Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Carboxyl/cholinesterase family represents a diverse group of serine hydrolases, including major drug-metabolizing enzymes such as Carboxylesterase 1 (CES1) and Carboxylesterase 2 (CES2), as well as Acetylcholinesterase (AChE) and Butyrylcholinesterase (BChE) (Source: UniProt, NCBI). These enzymes are defined by a conserved alpha/beta-hydrolase fold and a catalytic triad (Ser-Glu/Asp-His) that enables the efficient hydrolysis of a wide array of endogenous and exogenous esters, amides, and thioesters (Source: PubMed, PMID: 15603504). In human physiology, CES enzymes are primarily localized in the liver and gastrointestinal tract, where they serve as the primary gateway for the activation of many ester-based prodrugs, such as the antiviral oseltamivir and the chemotherapeutic irinotecan (Source: FDA, StatPearls). Beyond drug metabolism, members of this family like AChE are critical for regulating neurotransmission at cholinergic synapses, making them primary therapeutic targets for Alzheimer's disease treatments like donepezil (Source: NIH, PubChem). The activity of these enzymes is a major determinant of drug bioavailability and therapeutic efficacy; however, significant inter-individual variability exists due to genetic polymorphisms and susceptibility to inhibition by environmental toxins like organophosphates (Source: Wikipedia, Journal of Biological Chemistry). Understanding the substrate specificity and tissue distribution of this family is essential for optimizing drug design and predicting potential toxicological outcomes in clinical pharmacology.
Carboxylesterases facilitate the hydrolysis of various ester-containing prodrugs into their active pharmacological forms (e.g., converting oseltamivir to oseltamivir carboxylate). In the context of cholinesterases (AChE/BChE), drugs often act as inhibitors to increase the residence time of acetylcholine in the synaptic cleft to treat cognitive symptoms of dementia.
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carboxylesterase (CES) (CES).